ArticleJournal of immunology (Baltimore, Md. : 1950)2013
Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- SREBP1c modulates Treg immunobiology through a phospholipid-dependent adenosine pathway.The Journal of clinical investigation · 2026Article
- Regulatory T cell dysfunction and exhaustion in uveitis: immunometabolic mechanisms, microenvironmental drivers, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
- Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.Journal of hematology & oncology · 2022Review
- The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells.Frontiers in immunology · 2022Review
- Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease.International journal of molecular sciences · 2021Review
- Innate immunity orchestrates the mobilization and homing of hematopoietic stem/progenitor cells by engaging purinergic signaling-an update.Purinergic signalling · 2020Review
- Special Issue: G Protein-Coupled Adenosine Receptors: Molecular Aspects and Beyond.International journal of molecular sciences · 2020Article
- Pharmacological preconditioning with adenosine AScientific reports · 2020Article
- Use of Humanized Mouse Models to Investigate the Roles of Purinergic Signaling in Inflammation and Immunity.Frontiers in pharmacology · 2020Article
- [Rapamycin affect the apoptosis of splenic CD4Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- A Novel Method for Screening Adenosine Receptor Specific Agonists for Use in Adenosine Drug Development.Scientific reports · 2017Article
- Purinergic regulation of the immune system.Nature reviews. Immunology · 2016Review
- Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.Frontiers in immunology · 2016Review
- The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease.Frontiers in immunology · 2016Review
- Article
- A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment.Frontiers in immunology · 2016Review
- Graft versus host disease: New insights into A2A receptor agonist therapy.Computational and structural biotechnology journal · 2015Review
- Purinergic signalling and immune cells.Purinergic signalling · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Graft-versus-host disease (GVHD) remains a significant complication of allogeneic transplantation. We previously reported that the adenosine A(2A) receptor (A(2A)R) specific agonist, ATL146e, decreases the incidence and severity of GVHD in a mouse transplant model. There is increasing interest in treatments that increase CD4(+)CD25(high)Foxp3(+) regulatory T cells (Tregs) to suppress GVHD. Our current study found in vitro that A(2A)R selective agonists enhanced TGF-β-induced generation of mouse Tregs 2.3- to 3-fold. We demonstrated in vivo suppression of GVHD with specific A(2A)R agonists in two different murine GVHD transplant models associated with profound increases in both circulating and target tissue Tregs of donor origin. Three different A(2A)R agonists of differing potency, ATL146e, ATL370, and ATL1223, all significantly inhibited GVHD-associated weight loss and mortality. At the same time, Tregs shown to be of donor origin increased 5.1- to 7.4-fold in spleen, 2.7- to 4.6-fold in peripheral blood, 2.3- to 4.7-fold in colon, and 3.8- to 4.6-fold in skin. We conclude that specific activation of A(2A)R inhibits acute GVHD through an increase of donor-derived Tregs. Furthermore, the increased presence of Tregs in target tissues (colon and skin) of A(2A)R-specific agonist-treated mice is likely the mechanistic basis for the anti-inflammatory effect preventing acute GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.